Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Cll Sll clinical trials

Explore recruiting chronic lymphocytic leukemia small lymphocytic lymphoma cll sll clinical trials.

Recruiting chronic lymphocytic leukemia small lymphocytic lymphoma cll sll studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Cll Sll trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Global Multicenter, Open Label, Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination with Acalabrutinib versus Immunochemotherapy in Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA-2 Study)

Spain, Bulgaria, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

France, Sweden, Czechia, Austria, Belgium, Germany +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Poland, France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

Hungary, Sweden, Belgium, France, Ireland, Czechia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab

Italy, Austria, Spain, Ireland, Czechia, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Cll Sll trials by city

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Cll Sll clinical trials

Recruiting chronic lymphocytic leukemia small lymphocytic lymphoma cll sll studies right now

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Global Trial in APG2575 for Patients With CLL/SLL

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Also recruiting in Europe

A Global Multicenter, Open Label, Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination with Acalabrutinib versus Immunochemotherapy in Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA-2 Study)

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Cll Sll trials by city

Other conditions